Body Vision Medical Receives Regulatory Approval for LungVision® in Brazil, Expanding Access to AI-Driven Advanced Imaging for Lung Cancer Diagnosis

WALTHAM, Mass., July 29, 2025 /PRNewswire/ — Body Vision Medical, a global leader in AI-powered intraoperative imaging, is proud to announce that its LungVision advanced imaging system has received regulatory approval from ANVISA, Brazil’s National Health Surveillance Agency. This approval marks another significant step forward in the company’s mission to improve early and accurate lung cancer diagnosis around the world.

Lung cancer remains a leading cause of cancer-related death in Brazil, responsible for approximately 29,000 deaths annually, according to data from the Brazilian National Cancer Institute (INCA). Late diagnosis continues to be a challenge, with the majority of patients diagnosed at an advanced stage, where curative treatment options are limited.

“Securing regulatory approval in Brazil is a key milestone in our expansion across Latin America,” said Benny Krauz, Vice President of Regulatory and Quality at Body Vision Medical. “We’re proud to partner with Supri to make LungVision available to Brazilian physicians and patients, and to help raise the standard of care for early lung cancer diagnosis.”

LungVision transforms any standard C-arm into an AI-powered 3D imaging system, giving physicians real-time navigation and enhanced visualization to perform more precise bronchoscopic biopsies. The technology supports earlier and more accurate diagnoses of pulmonary nodules—helping improve patient outcomes while keeping procedural costs low.

“We are excited to bring LungVision to Brazil,” said Marcos Ramin, CEO of Supri. “This innovative imaging platform aligns perfectly with our mission to offer meaningful medical technologies that improve lives. LungVision’s ability to support early detection and enhance biopsy accuracy represents a major advance for interventional pulmonology in Brazil.”

For more information about LungVision and its availability in Brazil, please contact Supri https://www.supri.med.br.

About Body Vision Medical

Body Vision Medical believes in saving lives through the globalization of innovative medical technology. LungVision provides AI-powered real-time image guidance to address the clinical need for early, definitive lung cancer diagnosis and to enable effective treatment of lung lesions via minimally invasive procedures.

Visit bodyvisionmedical.com to learn more and connect with us on LinkedIn.

About Supri

Supri is dedicated to delivering life-improving technologies that advance the quality of healthcare in Brazil. With a commitment to innovation, clinical excellence, and meaningful partnerships, Supri ensures physicians have access to the best tools to serve their patients.

Contact:

Mike Hostetler
+1.651.366.9584
info@bodyvisionmedical.com

View original content:https://www.prnewswire.com/news-releases/body-vision-medical-receives-regulatory-approval-for-lungvision-in-brazil-expanding-access-to-ai-driven-advanced-imaging-for-lung-cancer-diagnosis-302514865.html

SOURCE Body Vision Medical